Gnbt - joe moscato president of generex.......on july.... Dday??

[ilpensionato]

boooommmm

probabile ritest a breve dei 3 dollari

ciaoneee

 

[overtake]

Uplist su Nasdaq o Nyse?

Generex Provides Update to Pending 1:1 Stock Dividend
9:30 AM ET, 06/07/2019 - GlobeNewswire
MIRAMAR, Fla., June 07, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (HOME) (OTCQB:GNBT) (OTC Markets | Official site of OTCQX, OTCQB and Pink Markets), in response to the large volume of investor calls, today provided an update on its new 1:1 dividend that has been approved by the Generex Board of Directors and as previously announced, will be declared on June 20, 2019, subject to any necessary regulatory approvals. This dividend will be tied to a NASDAQ or NYSE stock listing and will be paid on the day the Company is up-listed. The Company plans to submit an up-list application to an exchange shortly after the June 21, 2019 shareholders conference call. Please note, for the dividend to be declared, certain non-float holding shareholders will have to waive their rights to receive the dividend; not all have provided written agreement at this time.

Joe Moscato, President and Chief Executive Officer of Generex said, “When we took control of Generex in January 2017, we had a 3-step plan to return the Company to a national stock exchange through reorganization as a healthcare and life science holding company: 1) transformation from a development company to an end-to-end solutions provider with products and services that flow through to proprietary market channels; 2) an acquisition strategy that integrates product and service companies that generate revenues, profits and intracompany synergies among the NuGenerex family of companies; and 3) building out the end-to-end healthcare model with an HMO. We hope to accomplish this last objective through establishing NuGenerex Chronic Care Solutions, an ophthalmology, podiatry, and chronic care management company with a multi-clinic endocrinology group in Arizona, and with the buildout of NuGenerex Health in conjunction with industry leaders in the space who have launched and sold multiple successful HMOs in the past.”

Mr. Moscato continued, “Paying this dividend to our shareholders upon the up-listing to a major exchange will complete our 3-stage plan and will set the future growth strategy in place. Our up-listing will enable Generex to advance our acquisition strategy and to complete the buildout of our planned managed care organization, grow our revenue streams, expand and develop our distribution channels, complete the geographic expansion of our MSO, and build a New Life Sciences Company. Management is confident that we will continue to execute on our plans, and with this dividend to shareholders, I’m quite happy to share our successes and future opportunities with our valuable shareholders. I look forward to providing further details and answering questions on our shareholders conference call on June 21, 2019. We will provide call-in information in a future announcement.”

About Generex Biotechnology Corp.Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immuno-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.









(0) (0)




Read More: Generex Provides Update to Pending - GNBT Generex Biotechnology Corp. #5456265 - Investors Hangout

 

[ilpensionato]

Quindi correggetemi se sbaglio, il titolo che avevo in ptf. con Directa (io ho appunto Directa) è stato tolto perchè privo di valore e dopo un tot di giorni senza che venga assegnato un ticker e il valore viene appunto cancellato, tale titolo verrà riemesso in un secondo momento oppure no?
In data 20 Giugno ci sarà il pagamento dei dividendi 1/1 (per ogni azione posseduta ne verrà emessa gratuitamente una nuova)
Dopo pochi giorni dal pagamento del dividendo chiederanno un uplist Su Nasdaq o Nyse.
Tutto corretto?

LA SITUAZIONE DOVREBBE ESSERE QUESTA
primo dividendo su GNBT con RS 1:20 andato in porto
secondo dividendo con NGIO con ratio 1 a 4 che diventerà operativo quando sarà pubblico, quindi le azioni ricompariranno
terzo dividendo su GNBT con ratio 1 a 1 quando verra fatto l'up list, il 20 prossimo credo ci sarà solo una conference dove diranno qualcosa ma credo che i tempi saranno ancora lunghetti e non immediati


detto questo GNBT ora patrimonializza 100 ml, alcuni mesi fa valeva 5 ml

 

[overtake]

LA SITUAZIONE DOVREBBE ESSERE QUESTA
primo dividendo su GNBT con RS 1:20 andato in porto
secondo dividendo con NGIO con ratio 1 a 4 che diventerà operativo quando sarà pubblico, quindi le azioni ricompariranno
terzo dividendo su GNBT con ratio 1 a 1 quando verra fatto l'up list, il 20 prossimo credo ci sarà solo una conference dove diranno qualcosa ma credo che i tempi saranno ancora lunghetti e non immediati


detto questo GNBT ora patrimonializza 100 ml, alcuni mesi fa valeva 5 ml

Gentilissimo Pensionato, volevo chiederti se potevi linkarmi nuovamente il post di discussione su GNBT dove interviene anche Joe. Quello che ho io su Investors è fermo a post #4050 e non posta più nessuno. Almeno mi pare. Grazie in anticipo. *

 

[ilpensionato]

Gentilissimo Pensionato, volevo chiederti se potevi linkarmi nuovamente il post di discussione su GNBT dove interviene anche Joe. Quello che ho io su Investors è fermo a post #4050 e non posta più nessuno. Almeno mi pare. Grazie in anticipo. *

funziona tutto, prova
ciao

 

[overtake]

funziona tutto, prova
ciao

Grazie tante.

Hai letto le note di Joe. Personalmente, nonostante non dica nulla di ciò che non è pubblico, itra le ricche dei suoi post, ho inteso che è certo di avere le carte in regola nonché i requisiti aziendali, per fare il salto sul Nasdaq. Cosa ne pensi Pensionato?
PS: io sto incrementando!

The official Nasdaq website and looked at the listing requirements as of Jan 2019. It looks like we quality under the Nasdaq Capital Market Tier, under option 2: Market Value of LIsted Securites Standard.

Requirements:
Stock holder's equity: $4 million
market value of publicly traded shares: $15 million
market value of listed securities: $50 million
publicly held shares: 1 millio
shareholders: 300
market makers: 3
BId price: either $4 or $2

** To qualify under the closing price alternative, a company must have: (i) average annual revenues of $6 million for three
years, or (ii) net tangible assets of $5 million, or (iii) net tangible assets of $2 million and a 3 year operating history, in addition
to satisfying the other financial and liquidity requirements listed above.

It also says the average uplisting time is 4-6 weeks, but if all ducks are lined up, it can be substantially shorter


Read More: I went to the official Nasdaq website - GNBT Generex Biotechnology Corp. #5462421 - Investors Hangout

 

[ilpensionato]

Gnbt - joe moscato president of generex.......on july.... Dday??

 

[ilpensionato]

È il primo post della discussione.... Dice tutto

 

[ilpensionato]

Per l incremento vedi tu.

 

[ilpensionato]

No dico.... Il titolo vola, joe ha fatto una cc della Maronna e qua nessuno dice nulla?
Dormite... Dormite..

 

[ewilly1]

No dico.... Il titolo vola, joe ha fatto una cc della Maronna e qua nessuno dice nulla?
Dormite... Dormite..

sono svegli, risusciteranno se arriva a 50 dollari

 

[overtake]

sono svegli, risusciteranno se arriva a 50 dollari

Buongiorno a tutti, per me a 50 nell’arco dell’anno no. Ma sui 8 potrebbe farlo entro anno sentendo CC Joe.

Generex Biotechnology Subsidiary Olaregen Therapeutix Receives American Podiatry Medical Associations “Seal of Approval” for Excellagen Wound Conforming Matrix
9:00 AM ET, 06/26/2019 - GlobeNewswire
MIRAMAR, Fla., June 26, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (HOME) (GNBT) (OTC Markets | Official site of OTCQX, OTCQB and Pink Markets), announced today that their subsidiary, Olaregen Therapeutix, Inc., received the prestigious “Seal of Approval” from the American Podiatric Medical Association (APMA) for their Cellular Tissue Product, Excellagen Wound Conforming Matrix. Founded in 1912, the APMA is the leading resource for foot and ankle health information. Currently, the organization represents a vast majority of the estimated 18,000 podiatrists in the U.S.

The APMA Seal of Approval/Acceptance Program evaluates the use of therapeutic agents and their adjuncts (pharmaceuticals) and regulated medical devices. The seal is granted to a product after the Podiatric Seals Committee, a standing committee of the American Podiatric Medical Association, evaluates and determines whether the product allows normal foot function and promotes quality foot health. Additionally, evidence of usefulness and safety must be established, either by an appropriately recognized laboratory or clinical investigation, or by the products meeting certain physical standards. A detailed review is conducted by each committee member on every product. The committee then sends its recommendation to the APMA Board of Trustees, which has the authorization to either accept or reject the recommendation.

Excellagen is an FDA- 510(k) cleared Cellular Tissue Product with an indication for the management of wounds including Diabetic Foot Ulcers. Excellagen is a ready to use 3-dimensional wound conforming matrix that supports a favorable wound healing environment. It is designed to accelerate granulation tissue growth by providing a structural scaffold for cellular migration and proliferation, and activates platelets, triggering the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biological mediator of wound healing.

Joe Moscato, CEO of Generex commented, “Receiving the “APMA Seal of Approval” is tremendous news for our subsidiary, Olaregen Therapeutix. The process for receiving the seal is a rigorous evaluation of clinical utility and value, so our customers can feel confident in choosing Excellagen to manage their hard to heal wounds knowing that our best in class product meets the high standards set by the APMA. In addition, this is a great affiliation with the APMA, and we look forward to working with them and all APMA member surgeons and podiatrists to help manage their diabetic foot ulcers using Excellagen. I would love to hear from APMA members about their experience in the use of Excellagen in managing their patients hard to heal wounds.”

Anthony Dolisi, CEO of Olaregen Therapeutix commented, “Our customers include surgeons, patients, their caregivers and payors. The APMA Seal of Approval strengthens our value with our customer base. With demonstrated superior clinical data and strong economic value, the seal adds additional reason on why we believe Excellagen will be a disruptive technology in the Regenerative Wound Care Market. Equally as important is the impact Excellagen makes on patients with hard to heal wounds that are difficult to manage causing a poor quality of life.”

Read More: Generex Biotechnology Subsidiary - GNBT Generex Biotechnology Corp. #5470459 - Investors Hangout

 

[eschite]

Proprio perché non si agita nessuno, vuol dire che ci sono buone possibilità che si vedano ottimi risultati, qui di pompatori neanche l'ombra. Sempre presente attendiamo lo sfondamento di quota 3.

 

[ewilly1]

Proprio perché non si agita nessuno, vuol dire che ci sono buone possibilità che si vedano ottimi risultati, qui di pompatori neanche l'ombra. Sempre presente attendiamo lo sfondamento di quota 3.

Ma nessuno ha più notizie di kyro?

 

[ilpensionato]

questo è il suo ultimo messaggio credo
Vedi l'allegato 2612331

 

[ilpensionato]

esattamente il giorno dopo l'up listing
Joe ha grandi progetti in testa, chi avra pazienza senza vendere subito secondo me avrà l'opportunita di fare un grande gain, opportunità che capita una volta nella vita

 

[eschite]

Ma nessuno ha più notizie di kyro?

io purtroppo no

 

[ilpensionato]

Guarda su GNBT tutti sono andati in perdita e quelli che stavano meglio avevano un pmc di 0.10, per questo era doveroso liquidare anche sui minimi per acquisire una forte minus valenza e poi ricomperare sui minimi (per esempio a 3 dollari ante rs 1-20 ossia 15 cent attuali) ….
Ma il punto non è questo: il vento è cambiato, ovviamente non saranno rose e fiori ma dico se riusciamo a fare sto benedetto up listing che riesce ad una società su mille e probabile che si faccia un salto importante.
Ricordo di un titolo che quotava pochi cents in OTC fecero l'up al nasdaq e fu oggetto di acquisizione a 6 dollari.
Loro partivano da pochi cents noi siamo partiti da 20 cents….fai tu le proporzioni….la data dell'up non la so...forse in estate

 

[ewilly1]

notizie sugli utili? sulla insulina spray?

 

[ilpensionato]

notizie sugli utili? sulla insulina spray?

sei rimasto indietro